Argus Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Key Points

• Argus cut its price target on Danaher to $230 from $265 while maintaining a buy rating—implying roughly a 29.7% upside—and several other brokers have trimmed targets even as the consensus remains a "Moderate Buy" with an average target near $240.70.
• Danaher beat quarterly EPS expectations ($2.06 vs. $1.94) but revenue slightly missed at $5.95 billion, and the company set FY2026 guidance of $8.35–$8.55 in EPS.
• Near-term headwinds include a $172.5M shareholder litigation settlement, rising short interest (~17.8%), integration and margin pressure from the Masimo acquisition, and about €3.0 billion of newly issued senior notes that boost long-term debt.

Danaher (NYSE:DHR - Get Free Report) had its target price lowered by Argus from $265.00 to $230.00 in a research note issued on Friday,MarketScreener reports. The firm currently has a "buy" rating on the conglomerate's stock. Argus' price target would suggest a potential upside of 29.72% from the stock's current price.

DHR has been the topic of a number of other research reports. UBS Group dropped their target price on Danaher from $270.00 to $250.00 and set a "buy" rating on the stock in a research report on Wednesday. TD Cowen decreased their price objective on shares of Danaher from $245.00 to $240.00 and set a "buy" rating for the company in a research note on Wednesday. JPMorgan Chase & Co. dropped their price objective on shares of Danaher from $275.00 to $245.00 and set an "overweight" rating on the stock in a report on Wednesday. Wolfe Research lowered their price objective on Danaher from $260.00 to $230.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 8th. Finally, The Goldman Sachs Group dropped their price target on shares of Danaher from $265.00 to $230.00 and set a "buy" rating for the company in a research note on Monday, April 13th. Eighteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $240.70.

Danaher Stock Performance

Danaher stock opened at $177.31 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.87. Danaher has a fifty-two week low of $175.00 and a fifty-two week high of $242.80. The company has a 50 day moving average price of $195.75 and a 200-day moving average price of $213.86. The company has a market capitalization of $125.49 billion, a PE ratio of 34.30, a P/E/G ratio of 2.42 and a beta of 0.95.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.94 by $0.12. The business had revenue of $5.95 billion for the quarter, compared to the consensus estimate of $6 billion. Danaher had a return on equity of 10.91% and a net margin of 14.89%.The business's quarterly revenue was up 3.7% on a year-over-year basis. During the same period in the prior year, the firm posted $1.88 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. As a group, equities analysts forecast that Danaher will post 8.43 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president owned 5,099 shares of the company's stock, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.80% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Tyche Wealth Partners LLC acquired a new stake in Danaher in the 3rd quarter worth about $462,000. Bank Pictet & Cie Europe AG raised its position in shares of Danaher by 25.4% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 366,481 shares of the conglomerate's stock valued at $83,895,000 after buying an additional 74,301 shares in the last quarter. Lockheed Martin Investment Management Co. boosted its stake in shares of Danaher by 49.4% in the third quarter. Lockheed Martin Investment Management Co. now owns 25,340 shares of the conglomerate's stock valued at $5,024,000 after buying an additional 8,380 shares during the period. Johnson Investment Counsel Inc. increased its stake in Danaher by 2.9% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 664,705 shares of the conglomerate's stock worth $131,784,000 after acquiring an additional 18,744 shares during the period. Finally, Resona Asset Management Co. Ltd. raised its holdings in Danaher by 4.6% in the 3rd quarter. Resona Asset Management Co. Ltd. now owns 513,288 shares of the conglomerate's stock valued at $100,071,000 after acquiring an additional 22,595 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Guggenheim reiterated a Buy rating on Danaher, supporting demand-side interest from institutional buyers. Guggenheim Reaffirms Buy
• Positive Sentiment: An analyst price-target lift to $232 signals buy-side upside vs. current levels, which can support the stock if investors focus on medium-term earnings guidance. Price Target Raised to $232
• Neutral Sentiment: Danaher priced ~€3.0 billion of euro-denominated senior notes across maturities (2028–2038). This raises liquidity for operations or M&A but increases long-term debt on the balance sheet. Senior Notes Offering
• Neutral Sentiment: Coverage pieces question whether the recent share weakness makes DHR an attractive value play — useful for long-term investors but not an immediate catalyst. Valuation Article
• Negative Sentiment: Danaher agreed to settle shareholder litigation tied to its post‑pandemic outlook for about $172.5M, a direct hit to cash and a reminder of past forecasting issues; that likely pressured sentiment. Settlement Report
• Negative Sentiment: Short interest rose ~17.8% to 8.18M shares as of April 15 (≈1.3% of float; short-interest ratio ~2.5 days), indicating increased speculative/hedged bearish positioning that can amplify downward moves.
• Negative Sentiment: Morgan Stanley trimmed its price target (from $270 to $255), and UBS issued a pessimistic forecast—both moves add analyst-driven downside pressure despite differing target levels. Morgan Stanley PT Cut UBS Forecast
• Negative Sentiment: Analysts/commentary flag Danaher’s Masimo acquisition as adding long-term potential but creating near-term margin and integration pressure, a nearer-term risk to earnings momentum. Masimo Deal Commentary

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.